Sunday Clark1, Wenhui Wei2, Susan A Rudders3, Carlos A Camargo4. 1. Department of Emergency Medicine, Weill Cornell Medical College, New York, NY. Electronic address: sunday.clark@gmail.com. 2. Sanofi US, Bridgewater, NJ. 3. Department of Pediatrics, Rhode Island Hospital, Alpert School of Medicine at Brown University, Providence, RI. 4. Department of Rheumatology, Allergy, and Immunology, the Department of Medicine, and the Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.
Abstract
BACKGROUND: Although reported risk factors for severe anaphylaxis include older age, presence of comorbid medical conditions, and concomitant medications, previous studies have used varying definitions for anaphylaxis and heterogeneous methodology. OBJECTIVE: To describe risk factors for severe anaphylaxis among US patients treated in emergency departments (EDs) or hospitals for anaphylaxis. METHODS: Individuals with an ED visit/hospitalization for anaphylaxis were identified from 2 MarketScan Research Databases using an expanded International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code algorithm. Eligibility for the current study required continuous medical and prescription coverage for at least 1 year before and after the index date. Severe anaphylaxis was defined as a reaction requiring hospital admission. RESULTS: Among 11,972 individuals, 2,622 (22%) had severe anaphylaxis. Unadjusted analysis showed that severe anaphylaxis was associated with older age and higher comorbidity burden. These patients were also less likely to have filled an epinephrine autoinjector (EAI) prescription or visited an allergist/immunologist, but more likely to have had an ED visit/hospitalization (any cause). On multivariable analysis, filling an EAI prescription (odds ratio [OR], 0.64; 95% CI, 0.53-0.78) or visiting an allergist/immunologist (OR, 0.78; 95% CI, 0.63-0.95) before the index event was associated with a lower risk of severe anaphylaxis, while any previous ED visit (OR, 1.18; 95% CI, 1.07-1.30) or hospitalization (OR, 1.55; 95% CI, 1.36-1.75) was associated with a higher risk of severe anaphylaxis. CONCLUSIONS: In this large cohort with an ED visit or hospitalization for anaphylaxis, 22% had severe anaphylaxis. Pre-index preventive anaphylaxis care (ie, EAI prescription fill and allergist/immunologist visit) was associated with a significantly lower risk, supporting the benefits of preventive anaphylaxis care in real-world practice.
BACKGROUND: Although reported risk factors for severe anaphylaxis include older age, presence of comorbid medical conditions, and concomitant medications, previous studies have used varying definitions for anaphylaxis and heterogeneous methodology. OBJECTIVE: To describe risk factors for severe anaphylaxis among USpatients treated in emergency departments (EDs) or hospitals for anaphylaxis. METHODS: Individuals with an ED visit/hospitalization for anaphylaxis were identified from 2 MarketScan Research Databases using an expanded International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code algorithm. Eligibility for the current study required continuous medical and prescription coverage for at least 1 year before and after the index date. Severe anaphylaxis was defined as a reaction requiring hospital admission. RESULTS: Among 11,972 individuals, 2,622 (22%) had severe anaphylaxis. Unadjusted analysis showed that severe anaphylaxis was associated with older age and higher comorbidity burden. These patients were also less likely to have filled an epinephrine autoinjector (EAI) prescription or visited an allergist/immunologist, but more likely to have had an ED visit/hospitalization (any cause). On multivariable analysis, filling an EAI prescription (odds ratio [OR], 0.64; 95% CI, 0.53-0.78) or visiting an allergist/immunologist (OR, 0.78; 95% CI, 0.63-0.95) before the index event was associated with a lower risk of severe anaphylaxis, while any previous ED visit (OR, 1.18; 95% CI, 1.07-1.30) or hospitalization (OR, 1.55; 95% CI, 1.36-1.75) was associated with a higher risk of severe anaphylaxis. CONCLUSIONS: In this large cohort with an ED visit or hospitalization for anaphylaxis, 22% had severe anaphylaxis. Pre-index preventive anaphylaxis care (ie, EAI prescription fill and allergist/immunologist visit) was associated with a significantly lower risk, supporting the benefits of preventive anaphylaxis care in real-world practice.
Authors: Michael M McNeil; Eric S Weintraub; Jonathan Duffy; Lakshmi Sukumaran; Steven J Jacobsen; Nicola P Klein; Simon J Hambidge; Grace M Lee; Lisa A Jackson; Stephanie A Irving; Jennifer P King; Elyse O Kharbanda; Robert A Bednarczyk; Frank DeStefano Journal: J Allergy Clin Immunol Date: 2015-10-06 Impact factor: 10.793
Authors: Anna Chen Arroyo; Lacey B Robinson; Rebecca E Cash; Mohammad Kamal Faridi; Kohei Hasegawa; Carlos A Camargo Journal: J Allergy Clin Immunol Pract Date: 2021-03-30
Authors: Corrado Mirone; Donatella Preziosi; Ambra Mascheri; Gianluigi Micarelli; Laura Farioli; Luca G Balossi; Joseph Scibilia; Jan Schroeder; Laura M Losappio; Maria G Aversano; Chrysi Stafylaraki; Michele Nichelatti; Elide A Pastorello Journal: Clin Mol Allergy Date: 2015-06-22
Authors: F Estelle R Simons; Motohiro Ebisawa; Mario Sanchez-Borges; Bernard Y Thong; Margitta Worm; Luciana Kase Tanno; Richard F Lockey; Yehia M El-Gamal; Simon Ga Brown; Hae-Sim Park; Aziz Sheikh Journal: World Allergy Organ J Date: 2015-10-28 Impact factor: 4.084